• Explore /
  • Poster
  • / Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.

Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.

Abstract Poster

Authors

null

Martin Gutierrez

Hackensack University Medical Center, Hackensack, NJ

Martin Gutierrez , Matthew David Hellmann , Matthew A. Gubens , Charu Aggarwal , Daniel Shao Weng Tan , Enriqueta Felip , Joanne Wing Yan Chiu , Jong Seok Lee , James Chih-Hsin Yang , Edward B. Garon , Andrea Basso , Hua Ma , Lawrence Fong , Alex Snyder , Jianda Yuan , Roy S. Herbst

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03516981

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS9117)

DOI

10.1200/JCO.2019.37.15_suppl.TPS9117

Abstract #

TPS9117

Poster Bd #

438b

Abstract Disclosures

Similar Posters

First Author: Melissa Lynne Johnson

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.

Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.

First Author: Carlos Rojas

First Author: Hidehito Horinouchi

First Author: Manuel Rodrigues